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http://dx.doi.org/10Acute graft-versus-host disease (aGVHD) results in significant morbidity and mortality after
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Noninvasive diagnostic and
prognostic tests for aGVHD are currently lacking, but would be beneficial in predicting
aGVHD and improving the safety of allo-HSCT. Circulating microRNAs exhibit marked sta-
bility and may serve as biomarkers in several clinical settings. Here, we evaluated the use of
circulating microRNAs as predictive biomarkers of aGVHD in lymphoma patients after
allo-HSCT from matched unrelated donors (MUDs). After receiving informed consent, we
prospectively collected plasma samples from 24 lymphoma patients before and after
unmanipulated MUD allo-HSCT; microRNAs were then isolated. Fourteen patients developed
aGVHD symptoms at a median of 48 days (range: 32–90) post-transplantation. Two patients
developed intestinal GVHD, eight cutaneous GVHD, and four multiorgan GVHD. The
microRNA expression profile was examined using quantitative real-time polymerase chain
reaction (qRT-PCR). MicroRNAs 194 and 518f were significantly upregulated in aGVHD
samples compared with samples taken from non-aGVHD patients. Remarkably, these upregu-
lated microRNAs could be detected before the onset of aGVHD. Pathway prediction analysis
indicated that these microRNAs may regulate critical pathways involved in aGVHD patho-
genesis. Considering the noninvasive characteristics of plasma sampling and the feasibility
of detecting miRNAs after allo-HSCT using real-time polymerase chain reaction, our results
indicate that circulating microRNAs have the potential to enable an earlier aGVHD diagnosis
and might assist in individualizing therapeutic strategies after MUD allo-HSCT. Nevertheless,
standardization of blood sampling and analysis protocols is mandatory for the introduction of
miRNA profiling into routine clinical use. Copyright  2016 ISEH - International Society
for Experimental Hematology. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Graft-versus-host disease (GVHD) represents the leading regimen, the stem cell source, and gender disparity [2].
cause of non-relapse mortality after allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT) [1]. Several risk
factors for the development of GVHD have been identified,
such as the degree of donor–recipient match at the human
leukocyte antigen (HLA) loci, the type of conditioninguted equally to this article.
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se (http://creativecommons.org/licenses/by-nc-nd/4.0/).
.1016/j.exphem.2016.03.005However, moderate to severe acute GVHD (aGVHD) still
occurs in up to 40% of patients receiving HLA-identical
grafts, and the incidence is higher among recipients of
matched unrelated donor grafts [3]. Limited progress has
been made in the treatment of aGVHD, and the outcome
for patients with steroid-refractory aGVHD is poor, with
a mortality rate approaching 70% and no therapy available
to improve survival [4]. For these reasons, aGVHD preven-
tion through improved prophylaxis strategies has been a
primary focus of patient management after allo-HSCT.
This highlights the importance of identifying predictive
markers of aGVHD in its early stages to decreaseatology. Published by Elsevier Inc. This is an open access article under the
Table 1. Characteristics of patients
Characteristic
GVHD group
(n 5 14)
Non-GVHD group
(n 5 10)
Median age 50 (22–65) 34 (18–56)
Median dose/kg
CD34þ 7.8  106
(5.9–11.4)
6.5  106
(3.3–9)
CD3þ 2.96  106
(1.47–5.46)
3  106
(1.58–4.48)
Disease type
Non-Hodgkin’s lymphoma 8 (57%) 4 (40%)
Hodgkin’s lymphoma 6 (43%) 6 (60%)
Donor type
Matched unrelated 14 (100%) 10 (100%)
Regimen type
Thiotepa-cyclophosphamide-
fludarabine
9 (64%) 5 (50%)
Thiotepa-cyclophosphamide 5 (36%) 5 (50%)
GVHD prophylaxis
Cyclosporin A–methotrexate 12 (85%) 10 (100%)
Cyclosporin
A–mycophenolate
2 (15%)
GVHD onset (day) 48 (32–90)
GVHD grade
Grade I 3 (22%)
Grade II 8 (56%)
Grade III 3 (22%)
Target organ
Skin 8 (58%)
Gut 2 (14%)
Multiple organs 4 (28%)
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nicians with a potential time window to abort the alloreac-
tive process at its beginning.
So far, no validated diagnostic blood test has proven able
to predict the onset of aGVHD. It has been reported that
increased concentrations of tumor necrosis factor (TNF) a
during allo-HSCT conditioning are predictive of aGVHD
[5], and elevated post-HSCT/pre-HSCT TNFa ratios at
day 7 are predictive of aGVHD [6–8] in the myeloablative
setting. Furthermore, increased concentrations of inter-
leukin (IL)-6 during the first 3 weeks after HSCT predicted
later onset of aGVHD [9]. Altered levels of the cytotoxic T-
cell proteins CD40L, CD8, and IL-2 receptor (IL-2R) at day
15 post-HSCT have been associated with subsequent devel-
opment of aGVHD [10]; however, these findings await
confirmation. In addition, increased soluble B cell-acti-
vating factor (sBAFF) concentrations in the early post-
HSCT period have been associated with a decreased risk
of developing aGVHD [11]. Proteomic studies led to the
identification of a panel of four informative proteins,
namely, tumor necrosis factor receptor 1 (TNFR1), IL-
2Ra, IL-8, and hepatocyte growth factor (HGF), whose
detection at the onset of aGVHD has diagnostic and prog-
nostic value [12]. These proteins are found at the onset of
the disease, but do not predict aGVHD development. The
same researchers have discovered GVHD biomarkers, spe-
cific to target organs, that allow different forms of aGVHD
to be distinguished [13,14].
MicroRNAs (miRNAs) emerged as a novel class of bio-
markers with potential clinical relevance. miRNAs are short
(22–25 nucleotides), noncoding RNAs that negatively
regulate gene expression at the post-transcriptional level
by binding to their target messenger RNA (mRNA) in a
sequence-specific manner [15,16]. MicroRNAs play an
essential role in fundamental biological processes, such as
differentiation, proliferation, apoptosis, and homeostasis
[17], and are involved in different diseases, including
cancer, that exhibit a tissue-specific deregulation pattern
[18]. MicroRNAs are shed into the bloodstream in a very
stable form and can be detected by miRNA profiling ap-
proaches such as quantitative real-time polymerase chain
reaction (qRT-PCR) and microarray [19–21]. Given their
tissue specificity and their stability in many body fluids, mi-
croRNAs have received a great deal of attention with
respect to their potential as minimally invasive biomarkers
for several conditions [22,23], including aGVHD [24].
Our intent was to perform a prospective observational
study in which levels of circulating plasma miRNAs
were assessed with a qRT-PCR-based high-throughput
miRNA array in lymphoma patients after allo-HSCT
from matched unrelated donors (MUDs). We planned to
identify noninvasive biomarkers able to predict aGVHD
at early stages after allo-HSCT, therefore enhancing ther-
apeutic success and increasing the life expectancy of al-
lografted patients.Methods
Patient characteristics and sample collection
Twenty-four patients were enrolled in a prospective study aimed at
the assesment of circulating miRNA levels in a high-throughput
fashion at several points before and after transplantation. Approval
was obtained from the institutional review board (Study No.
D255690 INT 97/11), and all patients gave their written informed
consent. The stem cell source for allo-HSCT was peripheral blood
in all cases. The conditioning regimen consisted of a combination
of thiotepa (10 mg/kg) and cyclophosphamide (100 mg/kg;
n 5 14), with the addition of fludarabine (120 mg/m2) in 10 cases
[25]. The grafts were in vivo depleted of T cells using rabbit anti-
thymocyte globulin (thymoglobulin 3.5 mg/kg/day on days 4
and 3) or alemtuzumab in 23 cases and one case, respectively.
Post-transplantation GVHD prophylaxis consisted of cyclosporine
A and short-course methotrexate (10 mg/m2 on day þ1, 8 mg/m2
on days þ3 and þ6; n 5 22) or cyclosporine A and mycopheno-
late (15 mg/kg three times daily starting from day 0; n 5 2). The
median graft composition was 6.9  106 CD34þ cells/kg (range
3.3–11.4) and 2.99  108 CD3þ cells/kg (range 1.47–5.46). Pa-
tient characteristics, conditioning regimens, donor type, and
aGVHD characteristics are summarized in Table 1. After giving
informed consent, 20 healthy donors were also included in the
study as the normal counterpart. To obtain plasma, peripheral
blood samples (3 mL) were collected in EDTA (BD Vacutainer,
K2 EDTA, Ref. 367856) and centrifuged within 1 hour at
1,200g for 10 min at 4C to spin down the blood cells. The
626 S. Gimondi et al./ Experimental Hematology 2016;44:624–634supernatant was transferred into microcentrifuge tubes, and centri-
fuged a second time at 12,000g for 10 min at 4C. The supernatant
was removed and stored at 80C in RNase/DNase-free tubes.
RNA isolation
Total RNA was extracted from 500 mL of frozen plasma samples
using the miRvana isolation kit (Applied Biosystems) with minor
modifications. Namely, samples were incubated 30 min at 56C in
the presence of proteinase K prior to RNA extraction to disrupt
protein complexes that may sequester circulating miRNAs. So-
dium dodecyl sulfate (SDS) 0.1% and 5 N acetic acid 0.06%
were added to the lysate as previously described [26] to further
promote the release of miRNAs from protein–nucleic acid
complexes.
MicroRNA expression profiling by qRT-PCR
Given the lack of a suitable method for quantification of circu-
lating microRNA, a fixed volume of total RNA was subjected to
reverse transcription using a TaqMan MicroRNA Reverse Tran-
scription Kit (No. 4366596, Applied Biosystems) and Megaplex
RT primers (Human Pool A, No. 4399966, Applied Biosystems)
according to the manufacturer’s protocol. The cDNA libraries
were pre-amplified using Megaplex PreAmp primers (Human
Pool A, No. 4399233, Applied Biosystems) and PreAmp Master
Mix (No. 4384266, Applied Biosystems) following the manufac-
turer’s instructions. Subsequently, they were combined with Taq-
Man Universal Master Mix and loaded into TaqMan Human
MicroRNA Array A (No. 4398965, Applied Biosystems), enabling
accurate quantitation of 377 miRNAs selected as the miRNAs
most commonly expressed by human cells. Real-time PCR was
performed on an ABI PRISM 7900HT sequence detection system
(Applied Biosystems). The threshold cycle (Ct) for each microflui-
dic card was calculated using the program SDS 2.2.2 (Applied
Biosystems), setting a threshold of 0.2 and an automatic baseline
from 5 to 16 cycles.
Normalization and data analysis
The data set was filtered by keeping only miRNAs with Ct values
#32 in all samples, reducing the number of miRNAs to be
analyzed from 377 to 113. Data normalization was carried out
by calculating the DCt (hereafter called ‘‘ratio’’) between each
unique pair of miRNAs in an iterative manner for each sample
(e.g., CtmiR1CtmiR2, CtmiR1CtmiR3, CtmiR1CtmiR4, and so on
for every miRNA, thus obtaining ‘‘reciprocal ratios’’) [27].
Considering only those miRNAs always detected in all groups
of patients (113 miRNAs), a total of 6,328 reciprocal ratios per
sample were obtained (total number of ratios 5 n  (n  1)/2,
where n is the number of miRNAs considered detected). Only ra-
tios with an interquartile range (IQR) $0.15 were kept for further
analysis. The final data set included miRNA data for 1,610 ratios
from 23 samples (one sample from the aGVHD group was
excluded because of poor data quality). The underlying assump-
tion in this approach is that the ratio between two miRNA expres-
sion levels would change among groups only if one of the two is
differentially expressed or if both are (e.g., one upregulated, the
other downregulated) [27]. To select the most reliable differen-
tially expressed ratios, we repeated the unpaired two-sample t
test with a leave-one-out cross-validation approach [28]. This con-
sisted of repeating the statistical test n times, where n is the num-
ber of samples, and excluding one sample each time. Only thoseratios with a nominal p value! 0.01 in all n cycles were consid-
ered statistically different. p values were adjusted for multiple
testing using the Benjamini–Hochberg false discovery rate
(FDR) method [29].
Hierarchical clustering was performed with Euclidean distance
and average linkage. A supervised classification of samples was
carried out using support vector machines (SVMs), as imple-
mented in the R package ‘‘e1071’’ [30,31]. Linear and radial basis
kernels were evaluated, with the cost and gamma (when required)
parameters sampled from 0.001 to 1,000 and from 105 to 105,
respectively, in decimal powers. The optimal combination of pa-
rameters was found using the leave-one-out cross-validation
method, with miRNAs found differentially expressed as input fea-
tures. To test for overtraining and to assess the significance of the
cross-validated accuracy, a nonparametric permutation test with
10,000 permutations of sample labels was performed taking into
account accuracies O0.78.
To retrieve the unique deregulated miRNAs, a correlation anal-
ysis using Pearson’s correlation coefficient between raw Ct values
from the identified ratios and the average expression level of each
group (represented by the mean Ct value) was performed. Accu-
racy, specificity, and sensitivity were computed to evaluate the
performances of the classification. All statistical analyses were
performed using the open-source statistical language R [32].
Pathway analysis
The biological role of miRNAs associated with aGVHD was
investigated through the use of IPA (Ingenuity Systems, www.
ingenuity.com). A p value ! 0.05 determined by Fisher’s exact
test was used to select statistically enriched significant results.Results
Patient characteristics and aGVHD assessment
We designed a prospective study based on the weekly
collection of plasma samples from 24 lymphoma patients
undergoing MUD HSCT. At the time of transplantation,
all patients were in complete remission (CR).
After transplant, patients were monitored weekly for
3 months and then monthly up to 6–12 months depending
on the patient’s medical condition. At each visit, a com-
plete blood cell (CBC) count; leukocyte differential count
(LDC); platelet count; liver and renal function tests; drug
level test; acute-phase protein monitoring; and cytomega-
lovirus (CMV), Epstein–Barr virus (EBV), and adenovirus
monitoring were performed, but there were no significant
differences between aGVHD and non-aGVHD patients
(unpaired t test p O 0.05), according to data from the
literature [12].
All patients reached full donor chimerism before day
28 after transplantation, as assessed by analysis of the var-
iable number of tandem repeats (VNTR) in peripheral
blood. Platelet recovery (count O20,000/mL) was
achieved at a median of day 9 post-transplantation (range
3–20); neutrophils reached values O500/mL on day 11
(range 3–17), indicating successful engraftment in all pa-
tients. Blood cell counts and immunophenotyping were
Figure 1. Study design.
Table 2. Prospective analysis of circulating miRNAs in allografted
patients
Time
Average number (range)
of amplifiable miRNAsa
Healthy donors 230 (219–249)
Allografted patients
1 month before HSCT 200 (152–242)
þ7 days post-HSCT 70 (68–75)
þ14 days post-HSCT 150 (140–156)
þ21 days post-HSCT 181 (154–193)
þ28 days post-HSCT 195 (190–214)
þ60 days post-HSCT 213 (207–234)
þ90 days post-HSCT 243 (212–250)
aAverage number of miRNAs detected after allo-HSCT, considering miR-
NAs with Ct values #32 amplifiable.
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only, available at www.exphem.org) and revealed no dif-
ferences between the patients developing aGVHD and
those not developing it (p O 0.05). Defined according to
the established guidelines [33], acute GVHD onset was
monitored at least weekly. The overall incidence of any
grade and type of aGVHD was 58% (14/24), with 8 pa-
tients developing cutaneous GVHD (grades I–III), 2
gastrointestinal GVHD (grade II), and 4 multi-organ
GVHD. Patient’s characteristics, treatments, and aGVHD
grades and types are summarized in Table 1. As expected
in a reduced intensity conditioning setting such as the one
we used, all patients developed aGVHD after day 30 post-
allo-HSCT (median: 48, range: 32–90). After a median
follow-up of 22 months, two patients died of multiple or-gan failure related to aGVHD, and two died of progressive
disease.
No significant correlation was found between the onset
of aGVHD and donor–recipient mismatches at HLA loci,
type of conditioning regimen, sex mismatch, and number
of CD34þ or CD3þ cells in the graft (Fisher’s exact test
and t test p O 0.05).
Prospective analysis of profiling of circulating miRNAs
in allografted patients
Global miRNA analysis was performed on 240 plasma
samples obtained from 24 lymphoma patients collected
1 month before allo-HSCT and from day 7 up to day 100
post-allo-HSCT. Analysis was also performed on plasma
samples collected from 20 normal subjects using TaqMan
Low Density Arrays (TLDA) Cards (Applied Biosystems;
Fig. 1).
No significant differences were observed in the analysis
of circulating miRNAs in patients before allo-HSCT and in
healthy donors. In pre-HSCT samples, we were able to
detect a mean of 200 miRNAs (range 152–242), and in
healthy donor samples, a mean of 230 miRNAs (range
219–249). The majority of these miRNAs (68.9%) were
present in both patient and donor samples at similar levels
of expression (unpaired t test p value O 0.05). This is
consistent with the absence of active disease at the time
of transplantation for all patients.
At day þ7 after allo-HSCT, a mean of 70 miRNAs of the
377 present on the card could be detected. At subsequent
points, this number tended to progressively increase, prob-
ably reflecting an increase in the number of circulating cells
during hematopoietic reconstitution (Table 2) [34]. The
number of miRNAs detected reached values comparable
to those of pre-transplantation samples between days þ60
and þ90 post-HSCT.
Because an ideal biomarker should be able to predict
aGVHD development, we focused on miRNA data obtained
at day þ28, as all patients developed aGVHD after this day.
At this follow-up point, the number of miRNAs detected in
628 S. Gimondi et al./ Experimental Hematology 2016;44:624–634the plasma of patients was significantly lower (195) than
that of healthy donors (236; mean values, p 5 4.278e-07;
Fig. 2A).
In addition, patients developing aGVHD (aGVHD
group) had a significantly smaller number of circulating
miRNAs compared with patients not developing aGVHD
(non-aGVHD group; 182 vs. 210, respectively, mean
values, p 5 0.003; Fig. 2B). In accordance with the smaller
number of miRNAs detected, these were also less abundant
in the aGVHD group as indicated by higher Ct values,
considering all 377 miRNAs on the card (mean Ct: aGVHD
patients, 25.8; non-aGVHD patients, 24.9; healthy donors,
23.1; Fig. 2C). Lower expression levels of circulating miR-
NAs were confirmed considering that only 113 miRNAs
were detected (Ct! 32) in all samples (mean Ct: aGVHD,
23.9; non-aGVHD, 22.0; healthy donors, 21; p 5 0.004;
Fig. 2D).Figure 2. Circulating miRNAs in aGVHD patients are shifted toward lower expre
in patients post-HSCT than in healthy donors. Moreover, the average number o
GVHD patients have a significantly smaller number of detected miRNAs comp
expression levels in the aGVHD group are lower, as indicated by higher values
Ct: aGVHD patients, 25.8; non-aGVHD patients, 24.9; healthy donors, 23.1)
(Ct ! 32) in all samples (mean Ct: aGVHD, 23.9; non-aGVHD, 22.0; healthy dProfiling of circulating miRNAs before aGVHD onset
identifies patients at high risk of developing the disease
To identify miRNAs selectively expressed in one of the two
conditions (aGVHD patients and non-aGVHD patients), we
labeled each miRNA as ‘‘detected’’ (Ct # 32) or ‘‘unde-
tected’’ (Ct O 32) in a given sample, and we determined
whether detected miRNAs were statistically significantly
associated with aGVHD status. Results from Fisher’s exact
test indicated that the presence or absence of a specific
miRNA was not significantly associated with aGVHD at
an FDR cutoff of 0.01. Data were normalized using a recip-
rocal ratio approach, as described under Methods, resulting
in the DCt values used as input for the subsequent analysis.
Comparison of the aGVHD and non-aGVHD groups
indicated that 30 ratios could clearly discriminate the two
biological conditions (Figs. 1 and 3). Specifically, the 30
ratios identified with a leave-one-out cross-validationssion levels. (A) The number of miRNAs expressed is significantly smaller
f miRNAs detected differs among the three biological groups. (B) Acute
ared with non-aGVHD patients and healthy donors. (C) Accordingly, the
of cycle threshold (Ct), considering all 377 miRNAs on the card (mean
. (D) These results were confirmed considering only miRNAs detected
onors, 21). In (A–D), p values (t test) are reported.
Figure 3. MicroRNA expression profiles can distinguish aGVHD from non-aGVHD samples. Hierarchical clustering analysis performed with the 30 ratios
differentially expressed is able to discriminate aGVHD from non-aGVHD samples as expected, although some of the aGVHD patients (aGVHD12, aGVHD8,
aGVHD9, aGVHD4, aGVHD5) are grouped in the non-aGVHD cluster.
629S. Gimondi et al./ Experimental Hematology 2016;44:624–634class comparison approach [28] (Table 3) were used to
perform a hierarchical clustering analysis that was able to
clearly separate aGVHD and non-aGVHD patients, with
the exception of 5 aGVHD cases that presented an expres-
sion profile closer to that of the non-aGVHD group (Fig. 3).
Identified miRNA panel discriminates aGVHD from
non-aGVHD patients with high accuracy
As the final goal of circulating miRNA studies is to develop
a diagnostic or prognostic predictor, we used SVMs to eval-
uate the ability of the panel of 30 ratios previously identi-
fied to discriminate between aGVHD and non-aGVHD
samples in a supervised manner. The list of 30 ratios was
used directly as input to build the SVM model. The best
trained model indicates that the 30 ratios obtained by
analyzing the plasma samples before aGVHD onset can
predict the development of aGVHD with an accuracy of
0.78, a specificity of 1, and a sensitivity of 0.62 (cross-vali-dated accuracy; p value5 9  104). Four aGVHD patients
were misclassified and erroneously assigned to the non-
aGVHD class (Fig. 4). Of note, three of them had grade I
aGVHD.
miR-194 and miR-518f are overexpressed in aGVHD
samples
After the normalization step, we considered the 27 unique
miRNAs involved in each of the 30 significant ratios to
determine which of them was actually deregulated in the
aGVHD class.
We performed a correlation analysis using Pearson’s cor-
relation coefficient between the raw Ct values of the miR-
NAs present in the 30 differentially expressed ratios and
the average expression levels of aGVHD and non-
aGVHD samples, and only miR-194 and miR-518f were
not significantly correlated with the average expression
value (miR-194: r 5 0.27, p 5 0.21; miR-518f: r 5 0.09,
Table 3. Leave-one-out cross-validated class comparison: miRNA ratios
differentially expressed among aGVHD and non-aGVHD patientsa
Ratio Fold change p value FDR
hsa-miR-194_hsa-miR-374b 1.13 0.0002 0.0597
hsa-miR-194_hsa-miR-590-5p 1.12 0.0004 0.0597
hsa-miR-194_hsa-miR-652 1.13 0.0006 0.0597
hsa-miR-26b_hsa-miR-194 1.15 0.0007 0.0597
hsa-miR-194_hsa-miR-744 1.11 0.0008 0.0597
hsa-miR-26a_hsa-miR-194 1.16 0.0009 0.0597
hsa-miR-106a_hsa-miR-194 1.13 0.0010 0.0597
hsa-miR-16_hsa-miR-194 1.15 0.0011 0.0597
hsa-miR-17_hsa-miR-194 1.14 0.0011 0.0597
hsa-miR-29c_hsa-miR-194 1.11 0.0013 0.0597
hsa-miR-20a_hsa-miR-194 1.13 0.0013 0.0597
hsa-miR-194_hsa-miR-484 1.12 0.0014 0.0597
hsa-miR-142-3p_hsa-miR-194 1.13 0.0014 0.0597
hsa-miR-126_hsa-miR-194 1.11 0.0016 0.0597
hsa-miR-185_hsa-miR-194 1.12 0.0017 0.0597
hsa-miR-194_hsa-miR-339-3p 1.12 0.0018 0.0597
hsa-miR-103_hsa-miR-194 1.14 0.0019 0.0597
hsa-miR-194_hsa-miR-328 1.12 0.0021 0.0647
hsa-miR-146b-5p_hsa-miR-194 1.12 0.0022 0.0647
hsa-miR-28-3p_hsa-miR-194 1.11 0.0023 0.0647
hsa-miR-191_hsa-miR-194 1.12 0.0024 0.0647
hsa-miR-194_hsa-miR-339-5p 1.14 0.0026 0.0651
hsa-miR-30c_hsa-miR-194 1.13 0.0028 0.0668
hsa-miR-133a_hsa-miR-194 1.14 0.0029 0.0668
hsa-let-7e_hsa-miR-194 1.13 0.0029 0.0668
hsa-miR-30b_hsa-miR-194 1.13 0.0030 0.0674
hsa-miR-194_hsa-miR-331-3p 1.10 0.0035 0.0691
hsa-let-7a_hsa-miR-194 1.16 0.0037 0.0719
hsa-miR-374b_hsa-miR-518f 1.13 0.0041 0.0730
hsa-miR-454_hsa-miR-518f 1.11 0.0042 0.0730
aThirty ratios selected with the leave-one-out cross-validation class com-
parison (p ! 0.01). Fold change, p value, and false discovery rate
(FDR) were calculated using all samples.
Figure 4. MicroRNA ratios and aGVHD prediction. SVM classification of
samples based on the 30 differentially expressed ratios. Dots represent the
decision values assigned by the SVM algorithm to each patient’s miRNA
profile at day þ28 post-HSCT. The decision value represents the confi-
dence that an SVM classifier has in classifying a given sample. A positive
value assigns the sample to the non-aGVHD class, a negative value to the
aGVHD class.
630 S. Gimondi et al./ Experimental Hematology 2016;44:624–634p 5 0.68). Of note, both were upregulated in subjects expe-
riencing aGVHD, suggesting a possible role for the two
miRNAs in aGVHD development, whereas the other miR-
NAs present in the 30 ratios were stable and can be consid-
ered housekeeping molecules. TaqMan array data were also
confirmed by single-assay RT-PCR.
Pathway analysis reveals regulatory role of miR194 and
miR518f in biological processes associated with aGVHD
pathogenesis
Investigation of the biological role of miRNAs is a chal-
lenging task that requires the identification of target genes
and the classification of these genes into functional cate-
gories or known pathways. Ingenuity Pathway Analysis
(IPA) was used to identify both miRNA target mRNAs
and the biological processes in which miR-194 and miR-
518f are involved. IPA revealed several possible pathways
altered at the transcriptional level or potentially modified
by miRNAs at the post-transcriptional level. Among the tar-
geted mRNAs, we could identify key molecules of the JAK-
STAT pathway, MAPK signaling, and NFKB pathway thatare well known for their role in aGVHD pathogenesis
[35,36] (Fig. 5B, C). Moreover, IPA analysis revealed
‘‘Wnt/b-catenin signaling’’ as the top canonical pathway
(Fig. 5A), suggesting that deregulation of this signaling
might play a key role in aGVHD pathogenesis [37].
Discussion
We investigated changes in the levels of circulating miR-
NAs after allo-HSCT in a selected cohort of lymphoma
patients receiving grafts from MUDs and correlated
them with the occurrence of aGVHD. Our study indicates
that the analysis of circulating miRNAs at early points af-
ter HSCT is feasible and can be performed using a simple
and broadly applicable technique such as qRT-PCR ampli-
fication. Comparison of pre-HSCT miRNA profiles with
those of healthy subjects did not reveal significant differ-
ences either in the number of miRNAs detected or in the
levels of expression, in accordance with the absence of
active disease in our patients at the time of transplanta-
tion. After HSCT, the number of detectable circulating
miRNAs is lower than that of healthy donors, but in-
creases progressively with time. This may reflect the im-
mune reconstitution process that physiologically occurs
after transplantation in which the number of circulating
cells gradually increases to reach the levels of healthy
subjects [34].
When attention is focused on day þ28 post-allo-HSCT,
global miRNA expression profiling was able to discriminate
subjects who later developed aGVHD in our patient cohort.
However, when considering the use of circulating miRNAs
Figure 5. Pathway and network analysis of miR-194 and miR-518f target genes performed with the IPA software. Global canonical pathway analysis re-
vealed that target genes of miR-194 and miR-518f are involved in pathways that could be related to aGVHD. (A) Data for canonical pathways with a p
value! 0.01, calculated using Fisher’s exact test, are shown. (B, C) IPA analysis of miRNA target mRNAs: (A) graphical presentation of ‘‘Infectious Dis-
ease, Cell Death and Survival, Cellular Growth and Proliferation’’ network (score 32, focus molecules 25); (C) Graphical presentation of ‘‘Cellular Devel-
opment, Embryonic Development, Hematological System Development and Function’’ network (score 30, focus molecule 24).
631S. Gimondi et al./ Experimental Hematology 2016;44:624–634as biomarkers, some aspects must be taken into account: (i)
the accuracy of circulating miRNA profiling is wholly
reliant on sample type, processing, and profiling method;
(ii) analytical variables, such as data normalization, have
the potential to bias results [38]; (iii) there is no validated
technique to quantify plasma miRNAs; and (iv) little
concordance is observed between similar and independent
studies [24,38].
Data normalization is a major challenge when analyzing
qRT-PCR results. Different strategies have been proposed
[39] such as the use of synthetic miRNA molecules as
spike-in controls to normalize expression levels of targetmiRNAs. These molecules, although useful in assay valida-
tion and quality control [40], do not take into account differ-
ences in template quality or efficiency of reverse
transcription reactions. In previous studies, miRNA expres-
sion was estimated by relative quantification using RNU6,
RNU6B, 18S, and miR-16 as internal controls [20]. Howev-
er, the stability of these molecules in plasma is controversial,
and in our study, many of the so-called invariant miRNAs
were almost undetectable. Selection of stable miRNAs by al-
gorithms designed to evaluate the variability of candidate
housekeeping miRNAs across samples is an alternative
approach to identify potential normalizers [41,42], together
632 S. Gimondi et al./ Experimental Hematology 2016;44:624–634with the global mean normalization method [43]. These
global normalization approaches are based on the assump-
tion that the same total amount of miRNAs is expected in
all samples and that only a small fraction of miRNAs is de-
regulated. When profiling circulating miRNAs, these as-
sumptions should be viewed cautiously as miRNAs exhibit
great variability in expression levels [44].
Consequently, although widely used in the literature,
these normalization methods are not ideal when analyzing
circulating miRNA profiling data. This implies that further
research is needed to identify suitable methods, and in this
context, a ratio-based approach has been proposed [27] in
which all miRNAs are used, in turn, as housekeeping.
This method has the advantage of limiting a priori assump-
tions, although high redundancy is generated, and the re-
sults from raw and normalized data should be interpreted
together to determine which miRNA has a relevant role
and which functions as a calibrator.
In the absence of a consensus and taking into account all
the pros and cons of the aforementioned normalization
methods, we tested all of them. Regardless of the normali-
zation approach used, the circulating miRNA profiles were
able to discriminate patients that will later develop
aGVHD. Bearing in mind the limitations of each method,
the reciprocal ratio approach was used to generate the
data in this study, as this approach overcomes issues
regarding quantity and quality of the starting material.
Comparison of the aGVHD and non-aGVHD classes re-
vealed that 30 ratios could clearly discriminate the two
biological conditions. Moreover, two unique miRNAs
(miR-194 and miR-518f) were found to be upregulated
in samples of patients who would later develop aGVHD
with respect to those not experiencing the complication.
Of interest, pathway analysis allowed for the identification
of 389 target genes for miR-194, and 34 target genes for
miR-518f. Among miR-518f target genes, we found
EGR-1, a transcription factor that modulates the expres-
sion of several genes involved in inflammation, neutrophil
and monocyte adhesion and chemotaxis, tissue repair,
regeneration, and development [45,46]. Moreover, miR-
194 targets include SOCS2, a key molecule of the JAK-
STAT pathway; MAPK family genes that are involved in
MAPK signaling, TCR signaling, and the NFKB pathway;
and CXCL3, chemokine ligand 3, a molecule involved in
cytokine–cytokine receptor interaction and chemokine
signaling, a crucial step in aGVHD pathogenesis [47]. In
addition, among the top significantly represented canoni-
cal pathways were Wnt/b-catenin signaling, TGFb
signaling, and Toll-like receptor signaling. Wnt/b-catenin
signaling has been reported to play an important role in
gastrointestinal epithelial regeneration after
chemotherapy-induced damage [37]. The TGFb pathway
is an important modulator of immune responses, with
direct consequences for GVHD pathophysiology [48].
Toll-like receptors (TLRs) are important components ofinnate immunity and are known for sensing various micro-
bial ligands or danger signals (such as those subsequent to
a conditioning regimen), especially in the gut. Taken
together, these results suggest that targeting and subse-
quent downregulation of genes involved in the aforemen-
tioned pathways might be of interest in a GVHD context.
To date, only one study by Xiao et al. has analyzed
plasma miRNAs as potential biomarkers for aGVHD using
a similar qPCR platform [24]. Of note, elevated levels of
four miRNAs were detected before aGVHD diagnosis.
However, when we compared our results with those ob-
tained by Xiao et al., there was no consistency. There are
several possible reasons for the lack of reproducibility be-
tween the two studies:
1. Patient characteristics: Xiao et al. analyzed plasma
samples from a heterogeneous group of patients,
including patients with diverse disease types at the
time of HSCT (both malignant and not) who under-
went related or unrelated HSCT after a reduced-
intensity or myeloablative conditioning regimen. In
contrast, our study focused on the analysis of a homo-
geneous sample group of 24 lymphoma patients un-
dergoing reduced-intensity, conditioning-unrelated
HSCT. All patients enrolled in our study were in com-
plete remission at the time of transplantation; there-
fore, we can exclude differences caused by a
primary malignancy. Moreover, we could not find
any differences among the subgroups of lymphoma
patients (Hodgkin’s and non-Hodgkin’s), suggesting
that the differences found at day þ28 post-HSCT
can be truly associated with aGVHD onset.
2. Sample preparation and miRNA profiling technique:
As outlined in a very recent review [49], a great source
of variability in miRNA assessment of body fluids is
represented by both the extraction methodology and
the analysis platform employed. Even though the sam-
ple collection and extraction methodology used by
Xiao et al. are comparable to ours, this is not true of
the profiling method. Xiao et al. used a SYBR
green-based qPCR platform, whereas we took advan-
tage of a TaqMan-based qPCR platform. The SYBR
green-based qPCR platform lacks specificity, while
probe-based chemistry qPCR provides several benefits
over dye-based technologies. The TaqMan low-density
array used in our study combines high levels of spec-
ificity and reproducibility, making it one of the best
choices for quantification of circulating miRNAs.
3. Normalization strategy: Xiao’s group employed a
traditional housekeeping gene normalization, using
Cel-miR-39 as endogenous control. On the other
hand, we decided to normalize our data by calculating
reciprocal ratios of the miRNA expression levels, thus
overcoming differences in template quantity and
quality.
633S. Gimondi et al./ Experimental Hematology 2016;44:624–634This preliminary study confirms that profiling of circu-
lating miRNAs early after allo-HSCT is feasible and could
be used to monitor aGVHD onset. Although our results
appear promising, we realize several concerns over the
use of circulating miRNAs as biomarkers: (i) the accuracy
of circulating miRNA profiling is wholly reliant on sample
type, processing, and profiling method; (ii) analytical vari-
ables, such as data normalization, have the potential to bias
results [38]; (iii) there is no validated technique to quantify
plasma miRNAs; (iv) frequently, little concordance is
observed between similar and independent studies [38].
One could obviously argue that the limited number of
patients included in our study as well as the diverse condi-
tioning regimens and patient characteristics might account
for the different results. The lack of concordance with pre-
vious works [24,38,50] also points to the need for standard-
ization of preanalytical and analytical variables in
circulating miRNA studies.
In conclusion, we believe that the utility of circulating
miRNAs in aGVHD prediction, diagnosis, and prognosis
is still questionable. Standardization and reproducibility
remain the first goals to be accomplished before miRNAs
are introduced as biomarkers in clinical practice.Acknowledgments
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Supplementary Table E1. Blood cell counts at day þ28 post-HSCTa
Cell population
Mean count, No./mL (range)
p valueaGVHD group Non-aGVHD group
White blood cells 4,550 (1,450–8,350) 3,150 (2,730–3,570) 0.55
Lymphocytes 425 (200–800) 550 (300–700) 0.59
Erythrocytes 3.3  106 (2.7–3.8) 3.1  106 (2.7–3.4) 0.71
Neutrophils 2,600 (1,600–4,000) 1,700 (1,500–3,000) 0.41
Platelets 211.7  103 (44–417) 235.5  103 (130–336) 0.86
CD3þ 59.72 (4.7–117.6) 107.5 (88.3–128.5) 0.3
CD3þ/CD4þ 21.19 (3.2–55.5) 36.86 (28.7–45.1) 0.45
CD3þ/CD8þ 30.8 (1.38–72.1) 51.92 (37.1–66.7) 0.42
CD56þ/CD16þ 114.2 (14.54–223.68) 257.2 (156.4–359) 0.23
CD3þ/CD56þ 8.57 (0.1–31.6) 13.4 (2.6–55.8) 0.74
CD14þ 2,112 (2.6–4,675) 1,362 (110.4–3,263) 0.7
aRoutine blood tests are reported along with immunophenotyping results. Mann-Whitney test was performed to assess differences between the aGVHD and
non-aGVHD groups.
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